BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
76.18
-0.50 (-0.65%)
Apr 21, 2026, 4:00 PM EDT - Market closed
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 24 analysts that cover BridgeBio Pharma stock have a consensus rating of "Strong Buy" and an average price target of $86.04, which forecasts a 12.94% increase in the stock price over the next year. The lowest target is $49 and the highest is $125.
Price Target: $86.04 (+12.94%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 8 | 8 | 8 | 7 |
| Buy | 10 | 12 | 13 | 15 | 17 | 18 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 21 | 21 | 23 | 25 | 25 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Initiates $100 | Buy | Initiates | $100 | +31.27% | Apr 9, 2026 |
| Mizuho | Mizuho | Buy Maintains $91 → $106 | Buy | Maintains | $91 → $106 | +39.14% | Mar 18, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $89 → $94 | Buy | Maintains | $89 → $94 | +23.39% | Mar 10, 2026 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Mar 10, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $86 → $95 | Strong Buy | Maintains | $86 → $95 | +24.70% | Feb 25, 2026 |
Financial Forecast
Revenue This Year
951.20M
from 502.08M
Increased by 89.45%
Revenue Next Year
1.65B
from 951.20M
Increased by 73.78%
EPS This Year
-2.02
from -3.78
EPS Next Year
0.61
from -2.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.3B | 2.4B | ||||||
| Avg | 951.2M | 1.7B | ||||||
| Low | 771.1M | 1.1B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 159.1% | 151.4% | ||||||
| Avg | 89.5% | 73.8% | ||||||
| Low | 53.6% | 13.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.23 | 3.01 | ||||||
| Avg | -2.02 | 0.61 | ||||||
| Low | -3.20 | -1.53 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.